News

Moderna said on Friday it is cancelling plans to build a messenger RNA manufacturing plant in Japan due to "changes in the ...
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.
Moderna (MRNA) stock in focus as the company cancels plans for an mRNA manufacturing plant in Japan amid a challenging ...
The two collaborated on research showing that quantum computing could greatly aid the design of mRNA-based medicines and ...
Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...
Moderna Japan had planned to build an mRNA drug plant at Shonan Health Innovation Park in Kanagawa prefecture. The company shelved the plan, citing weak demand for vaccines and a poor business ...
In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...
Moderna (MRNA) ended the recent trading session at $31.25, demonstrating a -2.95% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.01%. Elsewhere, the Dow ...
It's difficult to get motivated about buying a stock that's plummeted or a company that seems to be out of favor with the ...
Moderna's Spikevax vaccine has been fully approved for children with high-risk conditions, the first vaccine to do so.
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.